公开(公告)号：US20130243772A1

公开(公告)日：2013-09-19

申请号：US13672077

申请日：2012-11-08

Applicant: UCB PHARMA S.A.

Inventor： Ralph Adams ,  Pallavi Bhatta ,  Sam Phillip Heywood ,  David Paul Humphreys

IPC: C07K16/28 ,  C07K16/18

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2866 ,  C07K16/2878 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。

公开(公告)号：US20130183703A1

公开(公告)日：2013-07-18

申请号：US13812692

申请日：2011-07-28

Applicant: Bryan John Smith ,  Helen Marie Kirke

Inventor： Bryan John Smith ,  Helen Marie Kirke

IPC: G01N33/68

CPC classification number: C12Q1/37 ,  G01N33/6857 ,  G01N2333/96433

Abstract: A method of measuring acidic species generated by degradation of a Fab or Fab′ component of a Fab-PEG or a Fab′-PEG comprising the steps of: a) cleaving the PEG and linker from the Fab-PEG or Fab′-PEG with an enzyme; b) optionally separating the PEG and linker generated in step a) from the Fab or Fab′, to provide a Fab or Fab′; and c) quantitatively analyzing acidic species associated with the cleaved Fab or Fab′ and/or the cleaved PEG.

Abstract translation: 测量由Fab-PEG或Fab'-PEG的Fab或Fab'组分降解产生的酸性物质的方法，包括以下步骤：a）从Fab-PEG或Fab'-PEG中切割PEG和连接体， 一种酶; b）任选地将步骤a）中产生的PEG和接头与Fab或Fab'分离，以提供Fab或Fab'; 和c）定量分析与切割的Fab或Fab'和/或切割的PEG相关的酸性物质。

公开(公告)号：US08487101B2

公开(公告)日：2013-07-16

申请号：US12839752

申请日：2010-07-20

Applicant: Daniel Christopher Brookings ,  Martin Clive Hutchings ,  Barry John Langham

Inventor： Daniel Christopher Brookings ,  Martin Clive Hutchings ,  Barry John Langham

IPC: C07D495/04

CPC classification number: C07D495/04 ,  C07D519/00

Abstract: A series of thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

公开(公告)号：US08465744B2

公开(公告)日：2013-06-18

申请号：US12569700

申请日：2009-09-29

Applicant: Alastair David Griffiths Lawson ,  Andrew George Popplewell

Inventor： Alastair David Griffiths Lawson ,  Andrew George Popplewell

IPC: A61K39/395

CPC classification number: C07K16/245 ,  A61K47/60 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565

Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.

Abstract translation: 本发明涉及对IL-1β的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。

公开(公告)号：US20130102030A1

公开(公告)日：2013-04-25

申请号：US13632702

申请日：2012-10-01

Applicant: UCB PHARMA S.A.

Inventor： Ralph Adams ,  Andrew George Popplewell ,  Stephen Edward Rapecki

IPC: C07K16/46

CPC classification number: C07K16/468 ,  A61K39/3955 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。

公开(公告)号：US20130095098A1

公开(公告)日：2013-04-18

申请号：US13583999

申请日：2011-03-09

Applicant: Kerry Louise Tyson

Inventor： Kerry Louise Tyson

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/30

Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.

Abstract translation: 结合包含重链的人PD-1的人源化激动抗体，其中重链的可变结构域包含CDR-H1的SEQ ID NO：1中给出的序列，CDR-H2的SEQ ID NO：2中给出的序列 CDR-H3和重链框架区的SEQ ID NO：3中给出的序列来自人子组序列VH4 3-1 4-30.4 + JH4（SEQ ID NO：33）。 本公开还涉及用于产生所述抗体分子的抗体分子，组合物和方法的治疗用途。

公开(公告)号：US08378073B2

公开(公告)日：2013-02-19

申请号：US11994053

申请日：2006-06-29

Applicant: Sam Philip Heywood

Inventor： Sam Philip Heywood

IPC: C07K16/00

CPC classification number: A61K47/60 ,  C07K2317/55

Abstract: The present invention provides a process for attaching one or more effector molecules to one or more cysteines in a protein comprising: a) activating one or more cysteines in the protein by diafiltering the protein against a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds and b) reacting the treated protein with an effector molecule.

Abstract translation: 本发明提供了将一种或多种效应分子连接到蛋白质中的一个或多个半胱氨酸的方法，其包括：a）通过将蛋白质反渗透单硫醇还原剂或多硫醇还原剂来活化蛋白质中的一个或多个半胱氨酸 不能形成分子内二硫键，和b）使经处理的蛋白质与效应分子反应。

公开(公告)号：US20130018057A1

公开(公告)日：2013-01-17

申请号：US13508962

申请日：2010-11-11

Applicant: Roland Bürli ,  Alan Findlay Haughan ,  Mîzio Matteucci ,  Andrew Pate Owens ,  Gilles Raphy ,  Andrew Sharpe

Inventor： Roland Bürli ,  Alan Findlay Haughan ,  Mîzio Matteucci ,  Andrew Pate Owens ,  Gilles Raphy ,  Andrew Sharpe

IPC: A61K31/519 ,  A61P37/06 ,  A61P29/00 ,  A61P25/00 ,  A61P11/06 ,  A61P1/00 ,  A61P17/06 ,  A61P9/00 ,  A61P7/02 ,  A61P9/12 ,  A61P9/04 ,  A61P25/28 ,  A61P25/16 ,  A61P25/08 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P35/00 ,  A61P35/02 ,  A61P27/02 ,  C07D495/04

CPC classification number: C07D487/04 ,  C07D495/04

Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract translation: 由稠合的双环吡啶或嘧啶部分取代的一系列喹啉和喹喔啉衍生物，其通过任选连接于杂原子的亚烷基链连接，作为P13激酶的选择性抑制剂，因此在医学中有益，例如在治疗炎症 ，自身免疫性，心血管，神经退行性，代谢性，肿瘤学，伤害性感受性或眼科疾病。

公开(公告)号：US20130012515A1

公开(公告)日：2013-01-10

申请号：US13508964

申请日：2010-11-11

Applicant: Gilles Raphy ,  Roland Bürli ,  Alan Findlay Haughan

Inventor： Gilles Raphy ,  Roland Bürli ,  Alan Findlay Haughan

IPC: A61K31/53 ,  C07D401/12 ,  C07D473/34 ,  A61K31/52 ,  A61K31/506 ,  A61P27/02 ,  A61P37/00 ,  A61P9/00 ,  A61P25/28 ,  A61P3/00 ,  A61P35/00 ,  C07D487/04 ,  A61P29/00

CPC classification number: C07D401/12 ,  C07D473/02 ,  C07D487/04

Abstract: A series of fused bicyclic pyridine and pyrazine derivatives, substituted directly on the pyridine or pyrazine ring by a functional group attached via a sulphur-containing linkage, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Abstract translation: 一系列稠合双环吡啶和吡嗪衍生物，直接在吡啶或吡嗪环上被通过含硫键连接的官能团取代，作为P13激酶的选择性抑制剂，因此在药物中有益，例如在治疗中 炎症，自身免疫，心血管，神经变性，代谢，肿瘤，伤害性或眼科疾病。

公开(公告)号：US20120316324A1

公开(公告)日：2012-12-13

申请号：US13498017

申请日：2010-09-24

Applicant: Ralph Adams ,  Laura Hancock ,  Sam Phillip Heywood

Inventor： Ralph Adams ,  Laura Hancock ,  Sam Phillip Heywood

IPC: C07K16/46 ,  C07K16/18

Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond.

Abstract translation: 一种多价抗体融合蛋白，其包含免疫球蛋白部分，例如Fab或Fab'片段，对感兴趣的抗原具有第一特异性，并且还包含对于目标第二抗原具有特异性的两个单结构域抗体（dAb） VH / VL对，其中两个单结构域抗体通过二硫键连接。 还提供了通过二硫键稳定的特异性双特异性抗体融合蛋白和其他抗体片段。